报价延迟最少15分钟:2025/09/14 12:24 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.07 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.48/-0.43
|
|
企业价值
89.72M
|
| 资产负债 |
|
每股账面净值
0.10
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/09/14 12:24 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate,CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis. |
